|
The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients Clinical research trials and The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients. The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients  The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients
The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients
For Condition: HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) , Boehringer Ingelheim Pharmaceuticals
Synopsis: To assess the safety and tolerance of multiple oral doses of Nevirapine (BI-RG-587). To generate data on the pharmacokinetics and dose proportionality of Nevirapine with multiple dosing. To characterize the pattern of virological activity in vivo. Improvement in virological end points will be examined for association with dose and absorption. To determine whether development of resistance is reflected in return of virological activity and, if so, when markers reflect this resistance. To determine if improvements of immunological endpoints are detectable in the number of patients studied. A compound free of the toxic effects of nucleoside chain terminators such as zidovudine (AZT) may have an advantage over currently available treatments for HIV infection. Such a compound has further advantages if it is active against AZT-resistant isolates. Nevirapine (BI-RG-587) has shown in vitro inhibitory activity against HIV-1 reverse transcriptase (RT). The molecular mechanism of the RT inhibitory effect is hypothesized to be non-competitive inhibition due to its binding to an RT site distinct from those for the RNA template primer, the deoxynucleotide triphosphate or the RNase H catalytic site.
Details: A compound free of the toxic effects of nucleoside chain terminators such as zidovudine (AZT) may have an advantage over currently available treatments for HIV infection. Such a compound has further advantages if it is active against AZT-resistant isolates. Nevirapine (BI-RG-587) has shown in vitro inhibitory activity against HIV-1 reverse transcriptase (RT). The molecular mechanism of the RT inhibitory effect is hypothesized to be non-competitive inhibition due to its binding to an RT site distinct from those for the RNA template primer, the deoxynucleotide triphosphate or the RNase H catalytic site. This is a staggered dose escalation cohort trial which examines the safety, tolerance, pharmacokinetics and activity of Nevirapine (BI-RG-587) in patients with HIV infection. Groups of 10 patients must have completed 4 weeks of therapy without requiring dose interruption before the next dosage level can be initiated. All 10 patients must be enrolled at a lower dosage level before the next dosage level can be initiated. Patients discontinue antiretroviral therapy, after signing informed consent, 28 days prior to receipt of a first dose of Nevirapine. Screening lab tests, including p24 antigen and plasma viremia, and CD4+ cell count determination are performed 21 days prior to drug dosing in Part I. Patients are notified of screening laboratory measures that exclude them from study participation. Upon such notification patients have the option to resume prior antiretroviral therapy or to repeat those values in one week. Part II consists of two 8-hour intensive blood sampling periods plus frequent trough value blood samplings. Safety, trough value blood sampling, and activity assessments are performed in Part III. An assessment of dose-tolerance and of activity is made in Study Week 12 in order that patients may continue Nevirapine chronic therapy for an additional 12 weeks. The Final Visit in Part IV takes place on Study Week 24 to complete the trial. Patients who complete 24 weeks are offered the option to continue on Nevirapine chronic therapy at the initial or an altered dose on a separate open-label protocol.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Pentamidine or dapsone prophylaxis for Pneumocystis carinii pneumonia (PCP) in patients with a CD4+ cell count = or < 200 cells/mm3. - Antifungal prophylaxis with oral fluconazole or ketoconazole. - Antiviral prophylaxis with a maximum of 1 gram of oral acyclovir per day. - Acute therapy for intercurrent infections so long as that therapy is not an excluded medication of an excluded opportunistic infection. Patients must have: - Positive HIV antibody test results by ELISA. - Average of CD4+ cell count at 60 and at 21 days prior to study beginning = or < 400 cells/mm3. - Seven of 10 patients in each treatment arm must have p24 antigen levels = or > 70 pg/ml (> 50 pg/ml at U. of Mass. site only) or be plasma viremic. - Preserved hematologic, hepatic, and renal function as defined by required lab values. - Ambulatory performance score of = or > 70 Karnofsky. - Ability to voluntarily provide written informed consent prior to treatment. - Willingness and ability to follow protocol requirements. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Active cytomegalovirus disease. - Toxoplasmic encephalitis requiring suppressive therapy. - Mycobacteriosis requiring maintenance chemotherapy. - Visceral Kaposi's sarcoma requiring chemotherapy and/or irradiation. - Malignancy other than Kaposi's sarcoma or limited cutaneous basal cell carcinoma. - More than mild diarrhea (defined as more than transient or > 4 loose stools per day). Concurrent Medication: The following medications / substances may NOT be ingested up to one hour before or 4 hours after a Nevirapine dose: - Antacids (particularly those containing calcium carbonate). - Cimetidine. - Carafate. - Cholestyramine resin. - Alcohol and alcohol-containing substances. - Benzodiazepines (diazepam, triazolam). Excluded: - Any approved or investigational antiretroviral, immunosuppressive, or cytotoxic drugs. - Glucocorticoids and steroid hormones (including oral contraceptives). - Dicumarol, warfarin, and other anticoagulant medications. - Nitroglycerin. - Digitoxin. - Valproic acid. - Tolbutamide. - Doxycycline. - Chloramphenicol. - Isoniazid. - Any sulfonamide medications. Patients with the following are excluded: - History of clinically important disease other than HIV infection defined by the investigator as possibly putting the patient at risk during study participation. - Conditions listed in Exclusion Co-Existing Conditions and symptoms. - Having received any approved or investigational antiretroviral, immunosuppressive, or cytotoxic drugs or any other experimental drug with 4 weeks of study entry. - A positive zidovudine (AZT) detection assay performed 7 days prior to drug dosing will exclude patients from study participation. Prior Medication: Excluded within 4 weeks of study entry: - Any approved or investigational antiretroviral, immunosuppressive or cytotoxic drugs. - Glucocorticoids and steroid hormones (including oral contraceptives). - Dicumarol, warfarin, and other anticoagulant drugs. - Nitroglycerin. Digitoxin. - Valproic acid. - Tolbutamide. - Doxycycline. - Chloramphenicol. - Isoniazid. - Antiepileptics (phenobarbital and other barbiturates). - Trimethoprim / sulfamethoxazole (Bactrim). Risk Behavior: Excluded: - Patients whose use of alcohol or drugs is sufficient to impair compliance with protocol requirements.
Total Enrollment: 30
Location and Contact Information:
Univ of Minnesota
Minneapolis, Minnesota, 55455
United States
Univ of Massachusetts Med Ctr
Worcester, Massachusetts, 01655
United States
Univ of California / San Diego Treatment Ctr
San Diego, California, 921036325
United States
Additional Information:
Study ID Numbers: ACTG 164; 00744
Study Start Date:
Record last reviewed: December 1994
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000962
Other Hiv Infections Studies:
1. A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.
2. A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original study extended ONLY for patients previously enrolled on VEU 009)
3. Garlic in hyperlipidemia caused by HAART
4. A Study to Compare Three Doses of T-20 When Given in Combination with Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
5. A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients
Related Studies:
Other HIV Infections Clinical Trials
Other Minnesota Clinical Trials
Other Minneapolis Clinical Trials
The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients
|
|
|
|
|
|
|
|
